Department of Pathology, Fundeni Clinical Institute, Bucharest 022328, Romania.
"TituMaiorescu" University, Faculty of Medicine, Bucharest 031593, Romania.
J Immunol Res. 2020 Sep 29;2020:6148286. doi: 10.1155/2020/6148286. eCollection 2020.
This study is aimed at investigating tumoral and inflammatory cells and the significance of the prognostic factors of pancreatic ductal adenocarcinoma (PDAC); it is also aimed at determining the role of immunohistochemistry in the diagnosis and prognosis of this neoplasm. . 230 cases of pancreatic ductal adenocarcinoma were included in the study group; these cases were selected from the archives of the Department of Pathology of the Fundeni Clinical Institute over a ten-year period. Immunohistochemistry was performed using the following antibodies: MUC 1, CD 34, Factor VIII, CD 68, MMP-7, CEA, p21, p53, and Ki 67. . There were 133 male (57.8%) and 97 female (42.2%) patients included in this study, with ages between 20 and 81 years old (mean age: 58.2 years) and with tumors located in the pancreatic head ( = 196; 85.2%), pancreatic body ( = 12; 5.2%), and pancreatic tail ( = 20, 8.7%), as well as panpancreatic tumors ( = 2; 0.9%). Patients presented with early stages (IA and IB), with low pathologic grade (G1), with small size tumors (less than 1-1.5 cm), with tumors located in the head of the pancreas, (p53: negative; p21: positive; and CD 68: positive in peritumoral tissue), with low nuclear index (Ki 67 < 10%), without metastases at the time of surgery (had a better prognosis), and with a survival rate of about 7 months. . Immunohistochemistry is useful for an accurate diagnosis, differential diagnosis, and establishment of additional factors that might have a prognostic importance. It is recommended to study peritumoral tissue from the quantitative and qualitative points of view to increase the number of prognostic factors. This study represents a multidisciplinary approach, and it is a result of teamwork; it presents histopathological methods of examination of this severe illness and describes only a part of the scientific effort to determine the main pathological mechanisms of this neoplasm.
这项研究旨在调查胰腺导管腺癌 (PDAC) 的肿瘤和炎症细胞以及预后因素的意义;它还旨在确定免疫组织化学在这种肿瘤的诊断和预后中的作用。研究组纳入了 230 例胰腺导管腺癌病例;这些病例是从 Fundeni 临床研究所病理科的档案中选择的,时间跨度为 10 年。使用以下抗体进行免疫组织化学染色:MUC1、CD34、因子 VIII、CD68、MMP-7、CEA、p21、p53 和 Ki67。本研究纳入了 133 名男性(57.8%)和 97 名女性(42.2%)患者,年龄在 20 岁至 81 岁之间(平均年龄:58.2 岁),肿瘤位于胰头部(=196;85.2%)、胰体部(=12;5.2%)和胰尾部(=20;8.7%),以及全胰肿瘤(=2;0.9%)。患者处于早期阶段(IA 和 IB),病理分级较低(G1),肿瘤体积较小(小于 1-1.5cm),肿瘤位于胰头部,(p53:阴性;p21:阳性;CD68:肿瘤周围组织阳性),核指数较低(Ki67<10%),手术时无转移(预后较好),生存率约为 7 个月。免疫组织化学对于准确诊断、鉴别诊断和建立可能具有预后意义的其他因素是有用的。建议从定量和定性的角度研究肿瘤周围组织,以增加预后因素的数量。这项研究代表了一种多学科的方法,是团队合作的结果;它展示了这种严重疾病的组织病理学检查方法,并仅描述了确定这种肿瘤主要病理机制的科学努力的一部分。